AAAAI & ACAAI GUIDELINES Bundle (free trial)

Anaphylaxis 2016

AAAAI & ACAAI GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/636525

Contents of this Issue

Navigation

Page 25 of 27

26 Recommendation Rating Scale Strong Recommendation (S) A Strong Recommendation means the benefits of the recommended approach clearly exceed the harms (or that the harms clearly exceed the benefits in the case of a strong negative recommendation) and that the quality of the supporting evidence is excellent (Grade A or B) Clinicians should follow a Strong Recommendation unless a clear and compelling rationale for an alternative approach is present. Recommendation (R) A Recommendation means the benefits exceed the harms (or that the harms clearly exceed the benefits in the case of a negative recommendation), but the quality of evidence is not as strong (Grade B or C). Clinicians should also generally follow a recommendation but should remain alert to new information and sensitive to patient preferences. Option (O) An option means that, either well-done studies (Grade A, B, or C) show little clear advantage to one approach versus another, or that the quality of evidence that exists is suspect (Grade D). Clinicians should be flexible in their decision making regarding appropriate practice, although they may set bounds on alternatives; patient preference should have a substantial influencing role. No recommendation (N) No recommendation means there is both a lack of pertinent evidence (Grade D) and an unclear balance between benefits and harms. Clinicians should feel little constraint in their decision making and be alert to new published evidence that clarifies the balance of benefit versus harm; patient preference should have a substantial influencing role.

Articles in this issue

Archives of this issue

view archives of AAAAI & ACAAI GUIDELINES Bundle (free trial) - Anaphylaxis 2016